ESC 2009: Studies boost use of biomarker as heart disease prognostic
This article was originally published in Clinica
Executive Summary
Three trials have backed the measurement of secretory phospholipase A2 (sPLA2) as a means to predict heart disease patients' risk of adverse events. Much of the research was conducted by Aterovax, an emerging French company developing a blood test for sPLA2.